Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Gains from Investment Securities (2020 - 2025)

Treace Medical Concepts (TMCI) has disclosed Gains from Investment Securities for 6 consecutive years, with $7.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities rose 2099.3% year-over-year to $7.2 million, compared with a TTM value of $7.2 million through Dec 2025, up 1430.39%, and an annual FY2025 reading of $7.2 million, up 1430.39% over the prior year.
  • Gains from Investment Securities was $7.2 million for Q4 2025 at Treace Medical Concepts, up from $462000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $15.2 million in Q2 2022 and bottomed at -$417000.0 in Q3 2024.
  • Average Gains from Investment Securities over 5 years is $2.0 million, with a median of $263000.0 recorded in 2024.
  • The sharpest move saw Gains from Investment Securities soared 4835.52% in 2021, then plummeted 2853.85% in 2024.
  • Year by year, Gains from Investment Securities stood at $7.5 million in 2021, then crashed by 97.71% to $171000.0 in 2022, then plummeted by 92.4% to $13000.0 in 2023, then tumbled by 2853.85% to -$358000.0 in 2024, then skyrocketed by 2099.3% to $7.2 million in 2025.
  • Business Quant data shows Gains from Investment Securities for TMCI at $7.2 million in Q4 2025, $462000.0 in Q3 2025, and $289000.0 in Q2 2025.